Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Marginal Profitability Of Mature Products Not What It Used To Be – Pfizer CEO

  • News

Executive Summary

Unlike in the past, continued marketing expenditure is necessary to sustain growth for relatively mature products, Pfizer CEO Hank McKinnell said June 13

You may also be interested in...



Gardasil Reimbursement Issues To Be Resolved In Early 2007, Merck Says

Merck expects reimbursement issues for its human papillomavirus vaccine Gardasil to be resolved by early 2007, Merck Vaccines President Margaret McGlynn said Dec. 12

Gardasil Reimbursement Issues To Be Resolved In Early 2007, Merck Says

Merck expects reimbursement issues for its human papillomavirus vaccine Gardasil to be resolved by early 2007, Merck Vaccines President Margaret McGlynn said Dec. 12

Pharma Investors Need To Look Long Term, Especially With Pfizer – McKinnell

Pharmaceutical industry investors should be less concerned about short-term performance in a sector with an extended business cycle, Pfizer CEO Hank McKinnell said June 13

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS047320

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By